Comparison of effects of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol and Budesonide Formoterol powder inhalation in treatment of patients with stable chronic obstructive pulmonary disease
Objective:To compare effects of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol and Budesonide Formoterol powder inhalation in treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 90 patients with stable COPD who were diagnosed in this hospital from April 2022 to June 2023.They were divided into control group and observation group by using the random number table method,45 cases in each group.The control group was treated with Budesonide Formoterol powder inhalation,while the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol.The clinical efficacy,the lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC]levels,the dyspnea symptoms[St.George's respiratory questionnaire(SGRQ)]score,the COPD symptoms[COPD assessment test(CAT)]score,the 6 min walking[6 min walking test(6MWT)]distance,the quality of life[general quality of life comprehensive invetory-74(GQOLI-74)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.56%(43/45),which was higher than 75.56%(34/45)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FEV1,FVC and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the SGRQ and CAT scores of the observation group were lower than those of the control group,the 6MWT distance was longer than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the GQOLI-74 scores of psychological,physical,social function and material life in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol in the treatment of the patients with stable COPD can improve the total effective rate of treatment,the lung function index levels,the 6MWT distance and the quality of life scores,and reduce the dyspnea symptom scores and the COPD symptom scores.Moreover,it is superior to single Budesonide Formoterol powder inhalation treatment.
Chronic obstructive pulmonary diseaseStable periodBudesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosolBudesonide Formoterol powder inhalationLung functionQuality of lifeSymptom
NETL
NSTL
万方数据
